Fig. 2From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a studyCONSORT flow diagram. AD Alzheimer’s disease, AE adverse event, CSF cerebrospinal fluid, EEG electroencephalography, ITT intention to treat, mITT modified intention to treat, MRI magnetic resonance imaging, NTB Neuropsychological Test Battery, PP per protocolBack to article page